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 2 
Abstract 18 
There is growing evidence for the value of bacterial whole genome sequencing in hospital 19 
outbreak investigation. Our aim was to develop methods that support efficient and accurate 20 
low throughput clinical sequencing of methicillin-resistant Staphylococcus aureus (MRSA). 21 
Using a test panel of 25 MRSA isolates associated previously with outbreak investigations, 22 
we devised modifications to library preparation that reduced processing time by 1 hour. We 23 
determined the maximum number of isolates that could be sequenced per run using an Illumina 24 
MiniSeq and a 13 hour (overnight) run time, which equated to 21 MRSA isolates and 3 25 
controls (no template, positive and negative). Repeatability and reproducibility assays based 26 
on this sequencing methodology demonstrated 100% accuracy in assigning species and 27 
sequence type (ST) and detecting mecA. Established genetic relatedness between isolates was 28 
recapitulated. Quality control (QC) metrics were evaluated over nine sequencing runs. 29 
168/173 (97%) test panel MRSA genomes passed QC metrics based on the correct species 30 
assigned, detection of mecA and ST, and depth/coverage metrics. An evaluation of 31 
contamination in these 9 runs showed that positive and negative controls and test MRSA 32 
sequence files contained <0.14% and <0.48% of fragments matching another species, 33 
respectively. Deliberate contamination experiments confirmed that this was insufficient to 34 
impact on data interpretation. These methods support reliable and reproducible clinical MRSA 35 
sequencing with a turnaround time (from DNA extraction to availability of data files) of 24 36 
hours.  37 
 3 
Introduction 38 
There is growing evidence of the value of bacterial whole genome sequencing (WGS) in 39 
hospital infection control practice and outbreak investigation (1). Numerous retrospective 40 
studies have shown that bacterial sequencing provides the discrimination required to 41 
distinguish between isolates of the same lineage, overcoming this limitation of previous typing 42 
methods (2-7). There is also strong published support for its use to investigate carriage, 43 
transmission and suspected outbreaks in high-risk areas such as intensive care units (2, 6). 44 
Used early, this could lead to action that limits the size of an outbreak (6, 8). Furthermore, 45 
sequencing can exclude outbreaks where a cluster of patients positive for the same pathogenic 46 
species has arisen by chance (9), saving unnecessary infection control interventions and 47 
outbreak investigations. 48 
 49 
The benefit gained from using WGS during outbreak detection is likely to be greatest if the 50 
technology is embedded within healthcare institutions and performed with a rapid turnaround 51 
time. This has become increasingly feasible through technical advances in sequencing 52 
instruments and the availability of commercial kits and liquid handling robots that simplify 53 
DNA extraction and library preparation. The laboratory processing aspects of WGS are now 54 
within the capabilities of larger diagnostic laboratories. The technical feasibility of sequencing 55 
in real-time has been demonstrated previously at a tertiary care hospital in Germany, but the 56 
turnaround time was 4.4-5.3 days with a cost of ~£170 (10). Reducing this turn-around time 57 
to results and the cost of sequencing will be key to implementing sequencing in the clinical 58 
setting and having an impact on infection control. In our clinical microbiology laboratory at 59 
Addenbrooke’s Hospital in Cambridge, United Kingdom, we are developing the methods and 60 
processes to introduce routine WGS of targeted nosocomial pathogens in close to real-time to 61 
enhance our infection control practice. Here, we describe the development of laboratory 62 
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processing methodology for low throughput clinical sequencing of methicillin-resistant 63 
Staphylococcus aureus (MRSA).  64 
 65 
Materials and Methods 66 
Test panel isolates 67 
Twenty-nine bacterial isolates (27 S. aureus and 2 E. coli) were assembled into a test panel 68 
for the study (Table 1). The majority of S. aureus (n=25) were MRSA from two evaluations 69 
of sequencing at the Cambridge University Hospital NHS Foundation Trust hospital (CUH) 70 
(6,7). Twenty-one MRSA were selected from a 12-month study of MRSA-positive patients 71 
(7) to provide representation of the dominant clonal complexes in our setting (CC22, CC30 72 
and CC5), combined with a range of genetic relatedness. A further 4 MRSA (all sequence type 73 
(ST) 22) were from an outbreak in a special care baby unit (6). Also included were 4 reference 74 
isolates: MRSA HO 5096 0412, methicillin-susceptible S. aureus NCTC 6571, E. coli NCTC 75 
12241 and E. coli NCTC 10418. For sequencing, isolates were cultured from frozen stocks 76 
onto Columbia Blood Agar (CBA, Oxoid), incubated in air at 37°C overnight, and single 77 
colonies picked for DNA extraction and further processing. Table 1 indicates the isolates used 78 
in each sequencing run. 79 
 80 
Positive and negative controls 81 
Three controls were included in every sequencing run to monitor the ongoing performance of 82 
the entire testing process. These were a no template control, a positive control (MRSA 83 
MPROS0386) that is 115 core genome SNPs different from the MRSA HO 5096 0412 84 
mapping reference, and a negative control (E. coli NCTC12241). The no template control 85 
contained all assay components except for DNA and was used to verify the lack of 86 
contamination across reagents and samples. The positive control was used to control the entire 87 
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assay process and analytical accuracy. The negative control was used to assess cross-88 
contamination during processing and represented the non-target DNA sample to verify 89 
analytical specificity. In the first two runs an alternative E. coli control (NCTC10418) was 90 
used, but this had a low match to E. coli in Kraken (~22%) and was replaced by NCTC12241 91 
(>50% match). Fresh stocks of molecular grade water and phosphate-buffered-saline were 92 
opened each week. Other ‘reuse’ reagents were checked for bacterial contamination weekly 93 
by sub-culturing using a 1µl loop onto CBA and incubating overnight in air at 37°C.  94 
 95 
DNA extraction, library preparation and sequencing 96 
DNA was extracted using the QIAgen DNA mini extraction kit 97 
(https://www.qiagen.com/gb/shop/sample-technologies/dna/genomic-dna/qiaamp-dna-mini-98 
kit/#resources) following ‘Appendix D: Protocols for Bacteria’ ‘Isolation of genomic DNA 99 
from Gram-positive bacteria’ with the following amendments: the incubation with proteinase 100 
K was performed at 56°C for 30 minutes; and in the final elutions, 50ul distilled water was 101 
added with the full 5 minutes incubation. DNA was quantified using a Qubit fluorometer.  102 
Sequencing libraries were made using the Illumina Nextera DNA flex kit based on the 103 
manufacturer’s instructions (11), with several modifications to reduce processing time (see 104 
results). In the first 3 runs, the input DNA to library preparation was normalized to ~100ng, 105 
but thereafter we used a range of up to 500ng DNA. Libraries were sequenced on an Illumina 106 
MiniSeq with a run time of 13 hours (overnight) using the high output 150 cycle MiniSeq 107 
cartridge and the Generate Fastq workflow. Genomes were demultiplexed using the Generate 108 
Fastq workflow and the data transferred to an external 1TB USB-connected hard drive for 109 
further analysis. Ten sequencing runs were performed during this evaluation; the objective of 110 
each run is summarized in Table S1. 111 
 112 
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Sequence data analysis 113 
Multilocus sequence types (ST) of the MRSA isolates were identified using ARIBA version 114 
2.12.1 as described at https://github.com/sanger-pathogens/ariba/wiki/MLST-calling-with-115 
ARIBA. Species were determined using Kraken version 1 116 
(https://ccb.jhu.edu/software/kraken/) with the miniKraken database available at 117 
https://ccb.jhu.edu/software/kraken/dl/minikraken_20171019_8GB.tgz. The presence of 118 
mecA (accession number HE681097, position 2790560-2792566) was determined using 119 
ARIBA, with a minimum percentage identity of 70% required based on Ito et al. (12) , and a 120 
minimum of 90% of the gene length covered. All isolates were mapped to the MRSA HO 5096 121 
0412 CC22 reference (accession number HE681097) using SMALT 122 
(https://www.sanger.ac.uk/science/tools/smalt-0) with mapping and base calling performed as 123 
described previously (13) with the following modifications: kmer size 13, step size 6. The 124 
depth and percentage coverage of the mapping reference were determined using the script 125 
available at https://github.com/sanger-pathogens/vr-126 
codebase/blob/master/modules/VertRes/Pipelines/Mapping.pm. 127 
 128 
Sequence metrics for controls 129 
Controls were required to pass the following quality metrics. MRSA positive control: highest 130 
match to S. aureus using Kraken, assigned to ST22, mecA detected, minimum mean sequence 131 
depth of 20x and minimum 80% coverage of the mapping MRSA reference genome (HO 5096 132 
0412). E. coli negative control: highest species match to E. coli in Kraken, mecA not detected, 133 
no S. aureus ST assigned. No template control: contamination from any bacterial DNA of less 134 
than 95,000 fragments in Kraken. MRSA isolates from the test panel were required to pass the 135 
following metrics: highest match to S. aureus using Kraken, assigned to the correct ST, mecA 136 
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detected, minimum sequence depth of 20x and minimum 80% coverage of the mapping MRSA 137 
reference genome (HO 5096 0412).  138 
 139 
Optimizing the number of isolates per sequencing run 140 
We estimated that the maximum number of MRSA isolates in a single sequencing run was 24 141 
based on an expected total data output of 3.3-3.8Gb, an average MRSA genome size of 2.8 142 
MB 143 
(https://www.ncbi.nlm.nih.gov/genome/?term=Staphylococcus%20aureus[Organism]&cmd=144 
DetailsSearch) and a target of ~50x coverage (24 isolates would provide ~49x coverage). We 145 
estimated that 21 test MRSA isolates and three controls (E. coli, MRSA and no template) 146 
could be included per sequence run. This was evaluated by performing sequencing runs that 147 
contained either 14, 18 or 21 test MRSA isolates from the study panel plus the 3 controls. One 148 
MRSA isolate from the 21-test isolate run failed to produce sufficient DNA during extraction 149 
and the E. coli control was included twice.  150 
 151 
Repeatability and reproducibility 152 
Repeatability was evaluated by sequencing six MRSA isolates (HO 5096 0412, MPROS0386, 153 
SASCBU17, SASCBU18, SASCBU25 and SASCBU35) in triplicate in a single sequencing 154 
run. For each isolate, frozen stock was sub-cultured onto CBA, incubated in air at 37°C 155 
overnight, and three separate colonies taken forward for individual DNA extraction, library 156 
preparation and sequencing. Reproducibility was evaluated by sequencing 21 MRSA isolates 157 
from the test panel in three independent runs. Each isolate was sub-cultured onto CBA and 158 
incubated in air at 37°C overnight, after which three individual colonies were taken forward 159 
for DNA extraction, library preparation and sequencing, one for each sequence run. The entire 160 
process was performed by different laboratory staff on three different days. The resulting fastq 161 
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files were analysed as above. Isolates that failed QC metrics were excluded from further 162 
analysis (3/18 and 1/63 test isolates failed the repeatability and reproducibility assays, 163 
respectively, based on low depth/coverage.  164 
 165 
Definition of a correct result was based on species identification, ST assignment, detection of 166 
mecA, and identification of genetic relatedness based on the detection of single nucleotide 167 
polymorphisms (SNPs) in the core genome compared to the original sequence and the within-168 
run or between run-replicates. Genetic relatedness was determined based on mapping to a 169 
clonal complex (CC)-specific references, excluding positions denoted as ‘N’ because of failure 170 
to call a base. Each repeat and the original sequence data were mapped to a CC-specific 171 
mapping reference using SMALT (MRSA HO 5096 0412 (CC22) for ST22 and ST2371; 172 
MRSA252 (CC30, BX571856) for ST30; and N315 (CC5, BA000033) for ST5). Mobile 173 
genetic elements were removed using the files available at 174 
https://figshare.com/authors/Francesc_Coll/5727779 and the script available at 175 
https://github.com/sanger-pathogens/remove_blocks_from_aln. Single nucleotide 176 
polymorphisms (SNPs) were identified using the script available at https://github.com/sanger-177 
pathogens/snp-sites. SNPs were identified based on the following parameters: minimum 178 
number of reads matching the SNP = 4; minimum number of reads matching the SNP per 179 
strand = 2; ratio of SNP base to alternative base >0.75; variant quality >50; mapping quality 180 
>30. 181 
 182 
Diagnostic sensitivity and specificity were calculated, using the following definitions: true 183 
positives, the number of genetically related isolates based on the original data that cluster 184 
together based on the test data; false negatives, the number of genetically related isolates based 185 
on the original data that do not cluster together in the test data; true negatives, the number of 186 
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genetically unrelated isolates based on the original data that do not cluster together in the test 187 
data; and false positives, the number of genetically distant isolates based on the original data 188 
that cluster together based on the test data (14). Clustering was defined based on three SNP 189 
classifications: (i) Recent transmission highly likely, 0-10 SNPs different (based on a median 190 
within host diversity of 6 SNPs over a year (7) and an estimated mutation rate of 4 SNPs/core 191 
genome/year  (15), (ii) Recent transmission likely, 11-25 SNPs, and (iii) Recent transmission 192 
possible, 26-50 SNPs different (based on the definition of a cluster described by Coll et al. 193 
(7)). Isolates >50 SNPs different were classified as genetically unrelated. 194 
 195 
Analysis of contamination 196 
The impact on quality metrics from varying levels of DNA contamination during clinical 197 
MRSA sequencing was evaluated using intentional spiking experiments. One MRSA isolate 198 
from the test panel (MPROS1839 (ST22)) and E. coli NCTC 12241 were cultured and DNA 199 
extracted and quantified as described above. Donor DNA was inoculated into the recipient 200 
sample to achieve a final spiked concentration of 0%, 0.1%, 1%, 10% or 20% (see results for 201 
details of donor and recipient). Contamination with the spike was defined based on the number 202 
and proportion of fragments matching to S. aureus or E. coli based on Kraken. The effect of 203 
contamination was evaluated using this metric together with the proportion of the S. aureus 204 
CC22 reference covered during mapping, depth of coverage of the mapping reference, and 205 
mecA and ST detected by Ariba. Unintentional contamination from internal controls or 206 
external sources was evaluated based on the number and proportion of reads matching to other 207 
species in Kraken. 208 
 209 
Data availability 210 
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Sequence data generated during this study are available from the European Nucleotide Archive 211 
(https://www.ebi.ac.uk/ena) under the accession numbers listed in Table 1.  212 
 213 
Results 214 
Our aim was to develop methods that would support efficient and accurate low throughput 215 
MRSA sequencing in a routine microbiology laboratory in less than 24 hours (from DNA 216 
extraction to availability of sequence data). Key goals were to maximize the number of isolates 217 
sequenced per run, reduce processing time of DNA preparation, and evaluate quality controls, 218 
precision (reproducibility and repeatability), and contamination.  219 
 220 
Maximizing the number of isolates per sequencing run was evaluated by performing 221 
sequencing runs that contained either 14, 18 or 21 test MRSA isolates from the study panel 222 
plus the 3 controls, which were sequenced using the Illumina MiniSeq with a run time of 13 223 
hours. Median (range) sequence depth for the test MRSA isolates was 92x (33-247x), 63x (45-224 
77x) and 65x (18-107x), respectively, with a minimum of 87% of the genome covered (Table 225 
S2). One isolate in the 21 test MRSA run failed the QC metrics based on depth of coverage 226 
(17.9x), which on further evaluation could be explained by low input DNA (Table S2). Based 227 
on this, we used 21 test isolates plus 3 controls per run during the remainder of the study.  228 
 229 
We sought modifications to the manufacturer’s protocol for library preparation (Illumina 230 
Nextera DNA flex kit) that would reduce processing time while maintaining performance. We 231 
proposed that two steps could be changed: (i) the tagmentation (TAG program) and 232 
tagmentation stop (TSB incubation) steps each require 15 minutes incubation, which were 233 
reduced to 5 minutes each; (ii) Pooling of libraries is recommended after bead clean-up and 234 
size selection, but we pooled libraries after PCR and before the bead-cleanup and size 235 
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selection. Two sequencing runs of 21 test panel MRSA + 3 controls were compared, one of 236 
which used the original protocol and the other made both changes to the protocol. Data were 237 
compared for quantity of DNA added to the library preparation versus the size of the resulting 238 
fastq files and depth of coverage, as surrogates for the individual DNA quantity outputs from 239 
library preparation, which are unavailable with the modified protocol. Detailed results are 240 
provided in Table S3.  In summary, comparison of original versus modified protocol showed 241 
negligible difference. The median (range) fastq size for the original versus modified protocols 242 
were 171MB (77-208MB) following 174-480ng DNA input versus 112MB (90-133MB) 243 
following 90-384ng DNA input. The median (range) depth of coverage for the original versus 244 
modified protocols were 87x (37-99x) versus 56x (43-70x). Together, these resulted in a 245 
reduction in processing time from 3.5 to 2.5 hours for library preparation, taking the combined 246 
time for DNA preparation and library preparation to 4.5 hours. Subsequent runs used these 247 
modifications. 248 
 249 
Repeatability was based on concordance of assay results and quality metrics for six MRSA 250 
isolates sequenced in triplicate in a single sequencing run. This demonstrated 100% 251 
concordance in assigning species, ST and detecting mecA. Four of the six isolates were drawn 252 
from a study that investigated a single outbreak on an intensive care unit (6) and were 253 
previously identified as being 0 SNPs different (SASCBU17 and SACBU18), 5 SNPs different 254 
(SASCBU25), or unrelated to the outbreak (SASCBU35, >1,500 SNPs different from other 255 
isolates). The remaining two isolates were MRSA HO 5096 0412 and the positive MRSA 256 
control (MPROS0386). Zero SNPs were identified between the within-run replicates for all 257 
isolates, equating to a repeatability per replicate of 100%. Using the original published 258 
sequence mapped to the CC22 reference (HO 5096 0412) as the gold standard, all 6 isolates 259 
in triplicate had identical base calls to the original sequence (excluding positions denoted as 260 
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‘N’ because of failure to call a base), equating to a repeatability per replicate and per base pair 261 
of 100%. 262 
 263 
Reproducibility was evaluated by sequencing 21 test panel MRSA isolates in three 264 
independent runs. This demonstrated 100% accuracy in assigning species, ST and detecting 265 
mecA. Eighteen of the 21 isolates represented six distinct outbreaks encompassing four 266 
different STs (ST22, ST30, ST5 and ST2371) identified during 12 months of genomic 267 
surveillance (n=15) (7) or a single outbreak in an intensive care unit (n=3) (6) . Of the 268 
remainder, 2 isolates were not involved in these outbreaks based on low relatedness, and 1 269 
isolate was the mapping reference MRSA HO 5096 0412. There were 0 SNPs identified 270 
between between-run replicates, providing a reproducibility per replicate of 100%. Using the 271 
original published sequence when mapped to the CC22 reference as the gold standard, 18 272 
isolates were identical to the original sequence across replicates. The remaining three isolates 273 
showed a difference in SNPs compared with the original sequence: MPROS0292 (ST22) had 274 
1-2 SNPs different, one of which was reproduced in all three repeats and the other was 275 
reproduced in two repeats with an N base call in the remaining repeat. MPROS1125 (ST22) 276 
had 1 SNP different in one repeat with an N base call in the same position in the remaining 277 
two repeats. MPROS2335 was identical for two replicates but the third replicate had 10 SNPs. 278 
In comparison to the original sequence this provides an assay accuracy of 92.3% (60/65 279 
repeats), although the true accuracy is likely be higher as the majority of SNPs may be genuine 280 
based on their presence among repeats.  281 
 282 
We next sought to determine the diagnostic sensitivity and specificity for outbreak detection 283 
in each of the three reproducibility runs, using the genetic relatedness established previously 284 
(6,7) as the gold standard (Table S4). All test isolate pairs within each run were in the same 285 
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genetic relatedness category (0-10 SNPs, 11-25 SNPs, 26-50 SNPs, >50 SNPs) as isolate pairs 286 
in the original data. This was reproducible across all three runs and represents a diagnostic 287 
sensitivity and specificity for outbreak detection of 100%, which was retained across a range 288 
of definitions for genetic relatedness. The majority of isolate pairs were within 1 SNP of the 289 
expected SNP difference based on the gold standard. The exceptions were Cluster 3 (2 SNPs 290 
different between MPROS0046 and MPROS1125 in two runs relating to failure to call a base 291 
at one position, and a SNP in a region that was absent across the replicates but present at low 292 
coverage in the original sequence); and Cluster 4 (MPROS0688 and MPROS2335; 2 SNPs 293 
different in two runs due to two positions at which a base failed to be called; and 6 SNPs 294 
different in the final run. The isolate sequence MPROS2335 was genetically identical to a 295 
second isolate from the same patient sequenced by Coll et al. (7) but not included here. From 296 
this, we suspect within-host diversity of MRSA in this case, and sequencing of different 297 
colonies of the same lineage. 298 
 299 
Quality control metrics were evaluated for the assay controls and MRSA isolates from the test 300 
panel over nine sequencing runs (Table S5 provides further details). All three controls in each 301 
sequence run passed the required QC metrics. Of 173 S. aureus test panel MRSA isolates 302 
sequenced, 168 (97%) passed the QC metrics. The five failures were based on insufficient 303 
depth/coverage associated with low input DNA (n=2) or potential loss of DNA during library 304 
preparation (n=3). Excluding these 5 failed isolates and the control isolates, S. aureus was the 305 
top match in Kraken in all cases (median (range) 85.8% (77.2-89.3%), the median (range) 306 
depth was 59x (21–247x), and the median (range) proportion of the reference genome covered 307 
was 94.6% (86.3-100%).  308 
 309 
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We then undertook deliberate contamination experiments to allow us to estimate the impact 310 
of varying levels of DNA contamination from internal controls or external sources on quality 311 
metrics. Details of the donor and recipient DNA, the concentrations of spiked DNA and our 312 
findings are summarized in Table 2. Contamination of the no template control with increasing 313 
concentrations of MRSA DNA did not lead to the control erroneously passing the QC metrics 314 
for MRSA until the final spiked concentration reached 10% or greater.  This indicates that 315 
contamination of the no template control at 1% (which equated to 96,671 fragments matching 316 
S. aureus in Kraken) can be tolerated. Contaminating the positive MRSA control with 317 
increasing concentrations of E. coli DNA demonstrated that this could tolerate up to 10% 318 
contamination (which equated to 4.04% fragments matching E. coli in Kraken) before the 319 
MRSA QC metrics were not achieved.  320 
 321 
We also evaluated unintentional contamination in nine runs (excluding the deliberate 322 
contamination assay). All E. coli and MRSA control sequence data files contained less than 323 
0.14% of fragments matching another species (Table S6). For the test MRSA sequence files, 324 
matches to other staphylococcal species were identified in over half of samples (109/173, 325 
median 0.05%, range 0.01-0.48% of fragments). Very low-level matches (0.01-0.13%) to 326 
other species were also identified in specific files (Table S6). All isolates had less than 0.2% 327 
of fragments matching to anther species, with the exception of a single reference isolate of 328 
MSSA that had a match of up to 0.48% to Staphylococcus nepalensis. Based on the number 329 
of fragments in Kraken for the no template controls, and the proportion of fragments in Kraken 330 
for the remaining sequences, this demonstrates that, with the exception of the isolate above, 331 
all controls and test isolates had levels of contamination below 1% (0.4% of fragments) across 332 
the nine sequencing runs (Table S6).  333 
 334 
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Discussion 335 
Our aim was to develop and describe methods for low throughput clinical sequencing of 336 
MRSA using commercial kits and manual methods. Our rationale was that this could support 337 
wider uptake in smaller diagnostic laboratories that are not equipped to undertake high volume 338 
sequencing using automated robots. Whilst liquid handling robots are essential for high 339 
volume sequencing such as that increasingly performed by public health reference 340 
laboratories, the majority of routine clinical laboratories have yet to invest in sequencing 341 
pipelines with their associated capital and maintenance costs.  342 
 343 
An important objective was to enable a 24-hour turnaround time from DNA extraction to 344 
availability of sequence data. The combined time for DNA preparation and library preparation 345 
is 4.5 hours, followed by a 13-hour (overnight) sequencing run on the Illumina MiniSeq. This 346 
would support a pipeline of clinical sequencing in which relevant cultures were identified in 347 
a routine laboratory and processed including sequencing within a day. The methods described 348 
here are based on a single colony, which when implemented in routine practice could be 349 
obtained from the original diagnostic clinical plate. This turnaround time, in combination with 350 
a rapid automated analysis pipeline, would allow infection control to determine whether 351 
patients were involved in an outbreak or not the day after a positive culture. This could allow 352 
rapid instigation of enhanced infection control procedures when an outbreak is detected to 353 
prevent further spread of the outbreak, and prevention of infection control actions such as ward 354 
closures if a suspected outbreak could be refuted.  355 
 356 
We also maximised the number of MRSA per sequencing run to minimize the cost per isolate. 357 
Based on 21 clinical isolates per run with three controls, the price per clinical isolate is 358 
currently £70 for DNA extraction, library preparation and sequencing. Whilst individual 359 
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hospitals are unlikely to frequently reach 21 clinical MRSA isolates suspected to be involved 360 
in an outbreak, we suggest a paradigm shift whereby all patients identified as MRSA positive 361 
have an isolate sequenced, and whole-genome sequencing leads infection control actions. This 362 
would reduce the turnaround time for action since current outbreak detection relies on multiple 363 
time-consuming steps including manually identifying patients that have been in the same ward 364 
at the same time. Using whole-genome sequencing combined with automated analysis would 365 
rapidly pinpoint which patients are involved in an outbreak or not, defining the cases that 366 
infection control need to act on, and those that require no action. The combination of 367 
turnaround and cost are critical measures for clinical translation. Alternative sequencing 368 
instruments such as the Oxford Nanopore Technologies provide the option for further 369 
reductions in sequencing time (16), and over time the cost and turnaround time of sequencing 370 
will undergo further reductions. As costs fall, lower-throughput technologies such as the 371 
Illumina iSeq 100 may become viable for routine clinical laboratories with smaller sample 372 
numbers. 373 
 374 
We described the use and evaluation of assay controls, examined the impact of contamination 375 
on data interpretation and determined the extent to which we inadvertently contaminated the 376 
assay. All three controls passed the required QC metrics in every run, together with 97% of 377 
test panel MRSA isolates sequenced. High levels of contamination were required before the 378 
controls failed QC metrics, and levels of inadvertent contamination were low. Evaluation of 379 
precision showed 100% repeatability and reproducibility in assigning species and ST and 380 
detecting mecA. SNP detection was 100% repeatable, but reproducibility was less than 100% 381 
because of the detection of a small number of SNPs that were not present in the original 382 
sequence. These can be explained by minor heterogeneity in colonies prepared for independent 383 
sequencing, with similar findings reported previously based on sequencing of a range of 384 
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bacterial species (14). Importantly, diagnostic sensitivity and specificity for outbreak detection 385 
were 100%, indicating that the data generated accurately determined MRSA relatedness, 386 
which supports use of this assay during outbreak investigation. The parameters evaluated in 387 
this study were in line with the workflow for validation of whole-genome sequencing in 388 
clinical laboratories described previously, and obtained comparable results (14). 389 
 390 
Our findings indicate that the methods evaluated here can provide high quality data. The single 391 
largest impediment to clinical sequencing is lack of fully automated data interpretation 392 
software that has a rapid turn-around time and is suitable for use by non-experts. This will 393 
need to be addressed for routine clinical sequencing to become viable, and is currently being 394 
investigated by numerous groups and investigators. 395 
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Table 1. Panel of bacterial isolates used in the study. 482 
 483 
 484 
 485 
 486 
Sample name Accession number Control or Test isolate Species ST Original study Transmission clusters Run 1 Run 2 Run 3 Run 4 Run 5 Run 6 Run 7 Run 8 Run 9 Run 10
SASCBU35 ERR131801 Test isolate Staphylococcus aureus 22 Harris et al. Unrelated to Cluster 1 x x x x x x x x
SASCBU17 ERR72246 Test isolate Staphylococcus aureus 2371 Harris et al. Cluster 1 x x x x x x x x x
SASCBU18 ERR72247 Test isolate Staphylococcus aureus 2371 Harris et al. Cluster 1 x x x x x x x x x
SASCBU25 ERR108054 Test isolate Staphylococcus aureus 2371 Harris et al. Cluster 1 x x x x x x x x x
MPROS0386 ERR212946 Control isolate Staphylococcus aureus 22 Coll et al. Unrelated to Cluster 2 x x x (2) x x x x x x
MPROS1839 ERR715142 Test isolate Staphylococcus aureus 22 Coll et al. Cluster 2 x x x x x x x x x
MPROS2508 ERR715397 Test isolate Staphylococcus aureus 22 Coll et al. Cluster 2 x x x x x x x x
MPROS2264 ERR715156 Test isolate Staphylococcus aureus 22 Coll et al. Cluster 2 x x x x x x x x
MPROS2239 ERR715240 Test isolate Staphylococcus aureus 22 Coll et al. Cluster 2 x x x x x x
MPROS0292 ERR212846 Test isolate Staphylococcus aureus 22 Coll et al. Cluster 2 x x x x x x x
MPROS2066 ERR702160 Test isolate Staphylococcus aureus 30 Coll et al. Cluster 3 x x x x x x x x
MPROS1560 ERR737278 Test isolate Staphylococcus aureus 30 Coll et al. Cluster 3 x x x x x
MPROS0947 ERR714803 Test isolate Staphylococcus aureus 30 Coll et al. Cluster 3 x x x (2) x x x x
MPROS2402 ERR715316 Test isolate Staphylococcus aureus 30 Coll et al. Unrelated to Cluster 3 x x x x x x x
MPROS0541 ERR702114 Test isolate Staphylococcus aureus 5 Coll et al. Cluster 4 x x x x x x x
MPROS1125 ERR737419 Test isolate Staphylococcus aureus 5 Coll et al. Cluster 4 x x x x x x x
MPROS0046 ERR212783 Test isolate Staphylococcus aureus 5 Coll et al. Cluster 4 x x x x x x
MPROS0238 ERR204190 Test isolate Staphylococcus aureus 5 Coll et al. Cluster 4 x
MPROS2412 ERR715326 Test isolate Staphylococcus aureus 5 Coll et al. Cluster 4 x x
MPROS0158 ERR211966 Test isolate Staphylococcus aureus 5 Coll et al. Unrelated to Cluster 4 x x (2)
MPROS0688 ERR701921 Test isolate Staphylococcus aureus 22 Coll et al. Cluster 5 x x x x x
MPROS2335 ERR736981 Test isolate Staphylococcus aureus 22 Coll et al. Cluster 5 x x x x x
MPROS0659 ERR701905 Test isolate Staphylococcus aureus 22 Coll et al. Cluster 6 x x x x x
MPROS2044 ERR702173 Test isolate Staphylococcus aureus 22 Coll et al. Cluster 6 x x x x x
MPROS1689 ERR737479 Test isolate Staphylococcus aureus 22 Coll et al. Not applicable x x x x
H050960412 HE681097 Test isolate Staphylococcus aureus 22 Reference strain Not applicable x x x x x x x x x
NCTC 6571 ERR1100774 Test isolate Staphylococcus aureus Not available Reference strain Not applicable x x
NCTC 12241 ERR718772 Control isolate Escherichia coli Not applicable Reference strain Not applicable x (2) x x x x x x x
NCTC 10418 ERS523599 Control isolate Escherichia coli Not applicable Reference strain Not applicable x x
 22 
Table 2. Deliberate contamination of controls and MRSA test isolates 487 
Question Recipient Contaminant Evaluation of impact Interpretation 
Determine the effect 
of contaminating the 
no template control 
with increasing 
concentrations of 
MRSA DNA 
No template 
control 
Spiked with MRSA 
MPROS1839 DNA at a 
final concentration of 0, 
0.01 or 0.1%  
- Number of fragments matching S. aureus 
were 6, 6 & 20, respectively 
- Coverage of mapping reference 36.8-46.7%  
- Average depth 0x 
- Did not pass QC metric for MRSA 
No template control 
can tolerate up to 1% 
contamination with 
MRSA DNA 
No template 
control 
Spiked with MRSA 
MPROS1839 DNA at final 
concentration of 1% 
- Number of fragments matching S. aureus 
were 96,671 
- Coverage of mapping reference 99.3%  
- Average depth 7.5x 
- Did not pass QC metric for MRSA 
No template 
control 
Spiked with MRSA 
MPROS1839 DNA at final 
concentration of 10% or 
20% 
- Number of fragments matching S. aureus 
were 363,031 and 623,855, respectively. 
- Coverage of mapping reference 99.3% (at 
both concentrations) 
- Average depth 28.3x and 48.6x, respectively 
- Both passed QC metrics for MRSA based on 
depth/coverage, species identification, 
assignment to ST22 and detection of mecA 
Determine the effect 
of contaminating the 
MRSA control with 
increasing 
concentrations of E. 
coli DNA 
MRSA 
control 
Spiked with serial E. coli 
NCTC12241 DNA at final 
concentration of 0, 0.01, 
0.1, 1, 10 or 20%  
- MRSA control passed QC metrics at all 
spikes except 20%, when the proportion of S. 
aureus genome covered fell from 84.6-91.6% 
(0-10% contamination) to 77.8% (20% 
contamination) 
- Proportion of fragments matching E. coli was 
0.44, 4.02 and 8.19 at 1%, 10% & 20%, 
respectively 
Positive control can 
tolerate up to 10% 
contamination with 
E. coli DNA 
 488 
